FOLD Share Price

Open 6.11 Change Price %
High 6.43 1 Day 0.04 0.66
Low 5.98 1 Week 0.29 5.00
Close 6.09 1 Month -2.78 -31.34
Volume 2311957 1 Year -3.89 -38.98
52 Week High 9.99
52 Week Low 4.98
FOLD Important Levels
Resistance 2 6.51
Resistance 1 6.34
Pivot 6.17
Support 1 5.84
Support 2 5.67
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

FOLD Technical Analysis 4
As on 9th Dec 2016 FOLD Share Price closed @ 6.09 and we RECOMMEND Sell for LONG-TERM with Stoploss of 7.02 & Strong Sell for SHORT-TERM with Stoploss of 7.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
FOLD Target for December
1st Target up-side 8.07
2nd Target up-side 9.54
3rd Target up-side 11.01
1st Target down-side 3.89
2nd Target down-side 2.42
3rd Target down-side 0.95
FOLD Other Details
Segment EQ
Market Capital 229448784.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.amicustherapeutics.com
FOLD Address
FOLD
1 Cedar Brook Drive
Cranbury, NJ 08512
United States
Phone: 609-662-2000
Fax: 609-662-2001
Interactive Technical Analysis Chart Amicus Therapeutics, Inc. ( FOLD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amicus Therapeutics, Inc.
FOLD Business Profile
Amicus Therapeutics, Inc. (Amicus) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. It is focused on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy (ERT). Its approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein. Amicus is also conducting preclinical studies on the use of its pharmacological chaperone technology to treat Parkinson�s disease, with an initial focus on Parkinson�s disease patients who are also Gaucher disease carriers.